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Abstract
Background Lowe syndrome and Dent-2 disease are caused by mutations in the OCRL gene, which encodes for an inositol 5-
phosphatase. The renal phenotype associated with OCRLmutations typically comprises a selective proximal tubulopathy, which
can manifest as Fanconi syndrome in the most extreme cases.
Methods Here, we report a 12-year-old male with nephrotic-range proteinuria and focal segmental glomerulosclerosis on renal
biopsy. As a glomerular pathology was suspected, extensive investigation of tubular function was not performed.
Results Surprisingly, whole exome sequencing identified a genetic variant inOCRL (c1467-2A>G) that introduced a novel splice
mutation leading to skipping of exon 15. In situ hybridisation of adult human kidney tissue and zebrafish larvae showed OCRL
expression in the glomerulus, supporting a role for OCRL in glomerular function. In cultured podocytes, we found that OCRL
associated with the linker protein IPIP27A and CD2AP, a protein that is important for maintenance of the podocyte slit
diaphragm.
Conclusion Taken together, this work suggests a previously under-appreciated role for OCRL in glomerular function and
highlights the importance of investigating tubular function in patients with persistent proteinuria.
Keywords Lowe syndrome . OCRL . Podocyte . Proteinuria . Glomerular disease . FSGS
Introduction
The oculocerebrorenal syndrome of Lowe, also known as
Lowe syndrome, is a rare X-linked disorder caused by
mutations in the OCRL gene, which encodes for a type II
inositol polyphosphate 5-phosphatase [1]. With respect to
mortality, the most important phenotype in patients with
Lowe syndrome is kidney dysfunction, which is characterised
by a gradual decline in excretory renal function leading to
chronic kidney disease (CKD) [2, 3]. The renal tubular phe-
notype can also include hypercalciuria, bicarbonate loss with
consequent acidosis [2, 4] and presents as a spectrum from
selective proximal tubulopathy to overt Fanconi syndrome
[5]. Affected individuals also develop ocular defects (congen-
ital cataracts) and central nervous system involvement [6, 7],
as well as other features including post-natal growth retarda-
tion, muscular hypotonia and arthropathy in later life [5, 8].
The renal phenotypes associated with Lowe syndrome are
also observed in Dent disease, which is an X-linked proximal
tubulopathy characterised by low molecular weight protein-
uria, hypercalciuria, nephrocalcinosis and progressive CKD
[3, 9, 10]. Other features of proximal tubular dysfunction,
such as aminoaciduria, glycosuria and complete Fanconi syn-
drome, can occur in Dent disease but are less frequent com-
pared to Lowe syndrome [5, 11]. There are two forms of Dent
disease, with the most common caused by mutations in the
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less common type caused by mutations in OCRL (Dent-2
disease) [3, 12–14]. Dent-2 disease presents as a clinical in-
termediate between Lowe syndrome and Dent-1 disease [3,
12] and lacks the most overt clinical features of Lowe syn-
drome [15]. Mild or sub-clinical extra-renal manifestations
have been reported with Dent-2 disease and include peripheral
cataracts, intellectual disability and short stature [5, 8, 16].
This overlap of clinical phenotypes between Lowe syndrome
and Dent-2 disease is indicative of the heterogeneity ofOCRL
mutations.
Proximal tubulopathy is considered to be the primary renal
feature associated with Lowe syndrome and Dent-2 disease,
yet atypical renal phenotypes including glomerular dysfunc-
tion have also been reported. Kaneko et al. describe a child
presenting with persistent proteinuria whose renal biopsy his-
tology led to a presumptive diagnosis of idiopathic focal seg-
mental glomerulosclerosis (FSGS) [17]. However, low-
molecular weight urinary proteins were persistently high and
subsequent genetic investigations identified a novel OCRL
mutation. In the absence of extra-renal manifestations charac-
teristic of Lowe syndrome, a diagnosis of Dent-2 disease was
made [17]. A mutation in CLCN5, which is expressed in
podocytes [18], has also been identified in Dent-1 patients
presenting with nephrotic range proteinuria and FSGS on re-
nal biopsy [19–21], and in a recent review by van Berkel et al.,
glomerulosclerosis was detected in almost two thirds of pa-
tients with Dent disease [22]. Nephrotic-range proteinuria [22]
has been reported in several other studies of novel and known
pathogenic OCRL mutations [15, 16, 22, 23]. Taken together,
these findings fit with the current consensus that glomerular
dysfunction in Lowe syndrome and Dent disease is a reported
feature but it is considered to be secondary to the
tubulointerstitial disease [8, 22, 24–26].
In this study, we report the case of a patient who presented
with nephrotic-range proteinuria and FSGS. Surprisingly, ge-
netic analysis identified a splicingmutation inOCRL. Given the
predominant glomerular pathology on renal biopsy, we ex-
plored a possible role for OCRL in glomerular function. We
show that OCRL is expressed in podocytes in vivo and use
cultured podocytes to understand better the role of OCRL in
this cell type. Interestingly, we found in cultured podocytes that
OCRL associates with CD2AP, a protein that has an important
role in maintaining the glomerular slit diaphragm. Overall,
these findings suggestOCRL affects podocyte function directly.
Methods
Ethical approval
For use of normal human biopsy sections (see detailed
methods below), ethical approval was through the
Manchester Renal Biobank reference: 16/NW/019.
Cell culture
Conditionally, immortalised human podocytes generated by
Saleem et al. [27] were cultured at the permissive temperature
of 33 °C in RPMI-1640 medium with glutamine (Sigma, MO,
USA) supplemented with 10% FBS (v/v) and ITS. Upon
reaching 70–80% confluence, proliferating cells were
thermo-switched to 37 °C for 10–14 days to allow differenti-
ation of cells. Mesangial cells [28] were cultured in the same
medium as the podocyte cells at 37 °C for 5 days. Glomerular
endothelial cells [29] were cultured in EBM-2 medium
(Lonza, UK) supplemented with 5% (v/v) FBS and EBM2
bullet kit (Lonza, UK) growth factors, excluding VEGF, at
37 °C for 5 days.
Preparation of cell lysates and protein extraction
Cells were washed with ice-cold PBS and lysed with HMNT
buffer plus protease inhibitors (20 mMHEPES, pH 7.4, 5 mM
MgCl2, 0.1 M NaCl, 0.5% (w/v) Triton X-100). Cell extracts
were centrifuged at 14,000×g at 4 °C for 10 min, and the
supernatant was kept on ice until needed.
SDS-PAGE and Western blot analysis
Cell lysates from differentiated wild-type podocytes, glomer-
ular endothelial cells and mesangial cells were analysed by
SDS-PAGE on 4–12% Bis-Tris gels (Life Sciences).
Proteins were transferred to nitrocellulose membranes, and
endogenous OCRL was blotted using polyclonal anti-OCRL
(1:500 dilution, Lowe lab [30]) followed by anti-sheep Alexa
Fluor-conjugated secondary antibody (1:5000 dilution, Life
Technologies Ltd). Immunoblotted proteins were detected
using Odyssey infrared imaging system (LI-COR,
Biosciences UK Ltd.).
Immunoprecipitation of endogenous OCRL
and CD2AP
Protein-G Dynabeads (Life Technologies) were re-suspended,
and the supernatant was discarded. Anti-OCRL (1:200 dilu-
tion, Santa Cruz Biotechnology, SC-393577) or anti-CD2AP
(1:200 dilution, Santa Cruz Biotechnology, SC-9137) anti-
body, diluted in PBS with 0.02% Tween, was added to the
beads and incubated by rotation at 4 °C for 1 h. Fresh total
cell lysate (TCL) was added to the suspension, which was
further incubated by rotation at 4 °C for 4 h. The beads were
washed, and proteins were eluted from the beads with sample
buffer (5×) at 95 °C for 10 min. Samples were separated by
electrophoresis, and proteins were identified by immunoblot-
ting with anti-OCRL or anti-CD2AP followed by appropriate
species-specific Alexa Fluor-conjugated secondary antibody
(1:5000 dilution, Life Technologies Ltd.).
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Endogenous protein pull down
Glutathione S-transferase (GST)-tagged recombinant
IPIP27A or GST alone (Lowe lab [31]) was coupled to
glutathione-sepharose beads (GE Healthcare, UK).
Following incubation with rotation at 4 °C for 1 h, protein-
coupled beads were washed and centrifuged at 9000 rpm at
4 °C for 1 min and the supernatant was discarded. Fresh TCL
was added to the protein-coupled beads and following incu-
bation with rotation at 4 °C for 3 h, samples were centrifuged
at 9000 rpm at 4 °C for 1 min. Proteins were eluted from the
beads with sample buffer (5×) at 95 °C for 10 min. Samples
were separated by electrophoresis, and proteins were identi-
fied by immunoblotting with anti-OCRL or anti-CD2AP (as
described above), followed by anti-sheep Alexa Fluor-
conjugated secondary antibody (1:5000 dilution, Life
Technologies Ltd).
Zebrafish husbandry
Zebrafish were maintained and staged according to
established protocols [32] and in accordance with the personal
project license of Professor Martin Lowe (70/9091) and under
the current guidelines of the UK Animals Act 1986. Embryos
were collected from group-wise matings of wild-type AB
Notts.
In situ hybridisation
Whole-mount in situ hybridisation on zebrafish embryos was
performed as previously described (Thisse Thisse, Nat
Protocols, 2008). Digoxigenin-labelled anti-sense riboprobes
were made using T3 RNA polymerase transcription kits
(Roche Diagnostics). Probe templates for zebrafish ocrl and
human OCRL were generated by PCR amplification from
cDNA taken from 5 dpf zebrafish embryos and human breast
tissue, respectively. The primers used were as follows: F zfish
ocrl 5′-CTCTGGAAACTACCTGCCCA-3′, R zfish ocrl 5′-
GGATCCAATTAACCCTCACTAAAGGGCATTCG
AGACAGCGCTGAAA-3 ′ ; F human OCRL 5 ′ -
CAGTGAGAGACCCCTTCAGG-3′, R human OCRL 5′-
GGATCCAATTAACCCTCACTAAAGGGGGAACT
GAATAGCACGCTGG-3′. Note that on the reverse primers, a
T3 anchor sequence (GGATCCAATTAACCCTCACT
AAAGGG) was used to enable T3-mediated RNA synthesis
off the purified PCR product. For human kidney sections, the
same protocol used in zebrafish was performed but slides with
de-waxed kidney sections were prepared with a 30-min
Proteinase K (3 μg/ml in PBS) incubation at 37 °C followed
by two PBS washes and 15 min 0.2 M HCl incubation at
RT°C. Slides were washed a further two times in PBS, and
then, the in situ protocol was followed. Probe incubations
were performed with 100 μl of RNA/Hyb+ underneath a
coverslip.
Genetic studies
Samples were collected following informed consent. OCRL
Sanger sequencing and analysis of X-inactivation were per-
formed as previously described. For whole-exome sequenc-
ing, library preparation, sequencing and data generation were
performed in the Genomics Core Facility of the Biomedical
Research Centre at Guy’s and St. Thomas’ Hospitals and
King’s College London. DNA libraries were prepared from
3 μg dsDNA using SureSelect Human All Exon 50 Mb Kit
(Agilent Technologies). Samples were multiplexed (four sam-
ples on each lane), and 100 base pair paired end sequencing
was performed on Illumina HiSeq system. Sequence data
were aligned to the human reference genome using
Novoalign, and variants were called with SAMtools and an-
notated via multiple passes through Annovar. Exome se-
quencing data analysis was performed at the University of
Bristol (Academic Renal Unit) [33]. Variants of interest were
confirmed using Sanger sequencing (Eurofins MWG Operon,
Germany). The KAPA HiFi PCR Kit (Kapa Biosystems) was
used for the amplification.
Results and discussion
We report the index case of a 12-year-old male with persistent
proteinuria, renal impairment and FSGS on renal biopsy. The
patient presented with a high serum creatinine (99 μmol/l),
normal serum albumin (49 g/l) but elevated urine
albumin:creatinine ratio (ACR) (70–94 mg/mmol) and
protein:creatinine ratios (PCR) (160–330 mg/mmol). The dif-
ference between the PCR and the ACR is suggestive of tubu-
lar proteinuria; however, this was not formally investigated
and the patient proceeded to have a renal biopsy. This revealed
9 sclerosed glomeruli from 23, representing 39% sclerosis.
Two more glomeruli showed adherence of the glomerular tuft
to the Bowman’s capsule and other glomeruli showed signs of
mesangial hypercellularity and increased mesangial matrix
deposition. The tubules contained some proteinaceous mate-
rial, and some had blood cells present within the lumen but
tubular morphology was generally normal apart from slight
atrophic changes in three tubule profiles. Three medium-sized
arteries present within the biopsy were also normal, and the
interstitium showed mild expansion without fibrosis or the
presence of foam cells. Immunofluorescence on six glomeruli
was negative for IgG, IgA, Fibrinogen, C1Q, C3, Kappa and
Lambda. Electron microscopy revealed foot process efface-
ment and irregular in-folding of the glomerular basement
membrane. No tubular pathology was documented. Since
the clinical and biopsy findings were suggestive of a
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glomerular disorder, tubular dysfunction was not thoroughly
examined and so we cannot discount that further investigation
may have confirmed tubular dysfunction. However, from the
available results, there was no overt evidence of proximal
tubular dysfunction; urinary pH, serum calcium and glucose
levels were within normal ranges, as were serum bicarbonate
and phosphate levels and an ultrasound scan of the urinary
tract did not show nephrocalcinosis. The patient was treated
with the angiotensin converting enzyme (ACE) inhibitor enal-
april and has experienced several episodes of AKI, which
responded to withdrawal of ACE inhibition.
Interestingly, an older male sibling presented to the adult
service at a similar time to the index case but with severe acute
kidney injury (AKI) and a creatinine of 1000 μmol/l. He had
been given a presumptive diagnosis of IgA nephropathy at a
younger age when the family lived in Poland, and he had been
receiving treatment with the ACE inhibitor, ramipril. At presen-
tation with severe AKI, his serum albumin was within the nor-
mal range, his urine protein:creatinine ratio was mildly elevated
(60 mg/mmol) and he did not have further tests to investigate
tubular function. His biopsy revealed 7 out of 7 normal glomer-
uli but widespread acute tubular necrosis. His renal ultrasound
scan did not have evidence of nephrocalcinosis. He did not
recover renal function and he subsequently received dialysis
and transplantation.
Whole-exome sequencing of the index case revealed a var-
iant of OCRL on the X chromosome (c1467-2A>G) [33]. This
mutation is a hemizygous one base pair substitution located at
the acceptor site of intron 14. Subsequently, this intronic splice
mutant was confirmed in both the index case and the sibling by
Sanger sequencing (Fig. 1a) and was also identified in the un-
affected heterozygotemother. In silico analysis predicts that this
mutation abolishes the acceptor site of intron 14 to induce skip-
ping of exon 15 (Fig. 1b). From a panel of 53 known genes
associated with steroid-resistant nephrotic syndrome, no other
mutations were identified [33], implying that theOCRL variant
was the cause of the renal pathology observed. The index case
had short stature and was treated with growth hormone treat-
ment. Short stature is a common feature of Lowe syndrome, but
this patient lacked ocular and neurological abnormalities.
Given the nephrotic-range proteinuria and the histological pat-
tern of FSGS, we propose that thisOCRLmutation represents a
mild form of Lowe syndrome or Dent-2 disease.
As the index patient presented with a predominant glomer-
ular pathology on renal biopsy, we proceeded to investigate
further a role for OCRL in the glomerulus. Previous studies
have demonstrated the expression of OCRL to be ubiquitous,
and transcripts have been identified in the kidney [37, 38]. We
aimed to confirm previous findings and to better understand
the spatial distribution of glomerularOCRL transcripts in vivo
in two different vertebrates (human and zebrafish). To do this,
we performed in situ hybridisation on 5 days post fertilisation
zebrafish, which is an embryonic stage when the glomerulus
has fully formed [39]. ocrl expression in the zebrafish embryo
was detected at high levels in the gut, eyes, swim bladder,
neural tube, ventral fin mesenchyme, branchial arches and
the forebrain, midbrain and hindbrain (Fig. 2a). We also found
ocrl transcripts in the zebrafish glomerulus when analysed in
transverse section (Fig. 2a). These data suggest OCRL func-
tions in the glomerulus from the earliest stages of develop-
ment. We also performed in situ hybridisation on histological
sections of normal human renal biopsy tissue. We detected
OCRL transcripts in all cell types within the glomerulus
(mesangial cells, endothelial cells and podocytes; Fig. 2b).
In summary, we confirm the presence of OCRL transcripts in
glomerular cells in vivo and our analysis in zebrafish suggests
that OCRL functions from early stages of development in
vertebrates.
In order to investigate the biochemical interactions of
OCRL in glomerular cells, we adopted an in vitro approach.
Using Western blot analyses, we found OCRL protein in cul-
tured endothelial cells, mesangial cells and podocytes (Fig.
3a). To elucidate the protein-protein interactions of OCRL in
cultured podocytes, we performed immunoprecipitation and
protein pull-down experiments on these cells to isolate
interacting partners of OCRL. We found that OCRL co-
immunoprecipitates with the slit diaphragm protein CD2AP
in cultured podocytes (Fig. 3 b and c). Interaction between
these proteins is likely to be mediated by the linker protein
IPIP27A, which can bind to both OCRL and CD2AP in pull-
down experiments (Fig. 3 d and e), in agreement with findings
in other cell types [31, 40, 41]. CD2AP is a component of the
glomerular filtration apparatus in the kidney, localising to
nephrin and podocin protein bridges to maintain the slit dia-
phragm between adjacent podocyte foot processes [42–44].
Mutations in CD2AP cause glomerular diseases associated
with defective trafficking within the endocytic pathway [45].
We predict that the interaction between OCRL and CD2AP is
important in the regulation of endocytic trafficking, actin cy-
toskeleton dynamics andmaintenance of the slit diaphragm. In
support of this, endocytic processes in the podocyte play a
fundamental role in the development and maintenance of the
glomerular filtration barrier [46, 47]. Alternatively, the
OCRL-IPIP27A-CD2AP protein complex may function di-
rectly at the unique podocyte cell-cell junctions in order to
maintain the slit diaphragm. Given that CD2AP is crucial in
maintaining the integrity of the glomerular filter [48, 49], dis-
ruption of this protein complex in Lowe syndrome or Dent-2
disease may directly lead to podocyte injury and glomerular
proteinuria. In our patient case, the pathology was caused by
an exon 15 skippingmutation. This is the commonest exon for
reported OCRL mutations but is not in the domain where
IPIP27A binds (which is exons 21–22).
The glomerular phenotype observed in the index case may
therefore be a consequence of the heterogeneity of OCRL
mutations. Our patient study therefore adds to the reports that
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already exist that show the same mutation in OCRL does not
correlate with disease severity [23]. Another possibility is that
exon 15 skipping causes protein instability that diminishes the
IPIP27A binding, thus resulting in a glomerular phenotype
due to CD2AP mislocalisation or function. OCRL is also in-
volved in actin dynamics and endosomal trafficking through is
5-phosphatase activity that converts PtdIns(4,5)P2 to
PtdIns4P. As slit diaphragm formation requires endosomal
trafficking and actin polymerisation, we cannot rule out the
possibility that non-IPIP27A interactions by OCRL are also
required for maintenance of podocyte function.
Our results raise the possibility that defective OCRL can
directly cause a glomerulopathy. In support of this, we show
that OCRL is expressed in podocytes in vivo and is able to
interact with CD2AP, an important protein whose function is
required for intact glomerular function. The potential of glo-
merular dysfunction in patients with Lowe syndrome or Dent-
2 disease hints that caution should be given to how patients are
treated as further study is required to confirm that glomerular
phenotypes are directly caused by perturbed OCRL function
in podocytes. We suggest that treatment of disease-causing
OCRL mutations could be stratified based on biochemical
and genetic analyses. Confirmation of an OCRL mutation in
the presence of nephrotic-range proteinuria could be used ini-
tially to determine the therapeutic approach. For example,
inhibition of the renin-angiotensin system would not
Fig. 1 Genetic analysis identifies a novel splice mutant in OCRL. a
Chromatogram’s from Sanger sequencing showing the c1467-2A>G mu-
tation (highlighted red) detected in the index patient, sibling and hetero-
zygous mother. Top panel shows non-mutant sequence and the corre-
sponding intron exon boundary. b Schematic representation of splicing
outcomes for normal OCRL (top) and the index patient OCRL sequence
containing the c1467-2A>G mutation (bottom). Use of the Spliceport
predictive tool [34] showed a strong splice acceptor site on exon 15 in
the normal OCRL (+ 1.57), which is completely lost in the variant OCRL
(− 2.23) (for reference the splice acceptor values for exon 14 and exon 16
are also shown (black), these were unchanged in the variant). Three other
splicing predictive tools (SpliceSiteFinder-like, MaxEntScan [35] and
NNSPLICE [36], which are algorithms run on the bioinformatics inter-
face Alamut) also showed the OCRL variant abolished the splice acceptor
site (data not shown). Taken together, these programs strongly suggest
that the mature transcript of the OCRL variant will undergo exon skipping
of exon 15 to yield the mature transcript illustrated (right)
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significantly benefit low molecular weight proteinuria (indic-
ative of tubular dysfunction), yet there are reports of improve-
ment in proteinuria after commencing enalapril therapy in a
patient with Dent disease [21], supporting a therapeutic ap-
proach targeting a glomerular origin for proteinuria.
We also propose, in agreement with Copelovitch et al. [21],
that OCRL and CLCN5 be added to the list of genes tested
prior to renal biopsy in young males presenting with protein-
uria (including those with nephrotic-range), who do not have
hypoalbuminemia or oedema and once tubular proteinuria has
been evaluated. Moreover, nephrotic range proteinuria is as-
sociated with other tubular disease genes, such as CUBN [50],
and these genes should similarly be added to the gene list in
order to better guide the physician in their diagnoses and treat-
ment options. This genetic information will be beneficial in
avoiding the need for renal biopsy and in preventing exposure
to immunosuppressive therapies and their undesirable side
effects. The genetic diagnoses and appropriate management
Fig. 3 Immunoprecipitation and
protein pull-down analysis
showing interaction between
CD2AP, OCRL and IPIP27A. a
Western blot analysis showing
that OCRL is abundant in
cultured glomerular cells
(endothelial cells, mesangial cells
and podocytes). b, c Co-
immunoprecipitation experiments
using control antibody (IgG) or
antibodies to OCRL (b) or
CD2AP (c) demonstrating
interaction between the
endogenous proteins. d, e Protein
pull-downs using GST control or
GST-IPIP27A as bait showing
binding to endogenous OCRL (d)
and CD2AP (e). Glutathione S-
transferase (GST),
immunoprecipitation (IP)
Fig. 2 In situ hybridisation
detects OCRL expression in the
glomeruli of zebrafish and adult
human kidney tissue. a Top
panels show OCRL expression in
a whole-mount zebrafish embryo
(left panel, lateral view, anterior to
the left) and in transverse section
through the glomerulus (right
panel, highlighted with white
dotted outline) at 5 days post
fertilisation (dpf). b In situ
hybridisation of normal adult
human kidney tissue showing
OCRL expression within the
glomerulus. The left panel shows
a low magnification image with
glomeruli and proximal tubules
labelled. The right panel shows a
close-up view of the glomerulus
withOCRL expression labelled in
podocytes (black arrow),
mesangial cells (green arrow) and
endothelial cells (red arrow)
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of tubular versus glomerular proteinuria may also delay end-
stage renal disease in these patients. However, this requires a
thorough evaluation of both tubular and glomerular function
in patients who present with persistent proteinuria.
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